Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu3F8/GM-CSF Plus Isotretinoin in High-Risk Neuroblastoma
NCT03033303Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2017
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2017; status: completed.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03033303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033303.